TAP Uprima Erectile Dysfunction NDA Refiling Slated For 4Q, Abbott Says
Executive Summary
TAP will refile an NDA for the erectile dysfunction disorder drugUprima in the fourth quarter, Abbott Pharmaceuticals President Jeff Leiden, MD/PhD, told analysts on a first quarter conference call April 9
You may also be interested in...
Lilly Cialis Delay Clears Space For Bayer Nuviva: Extra FDA Caution Cited
The delay in the FDA review of Lilly/Icos' Cialis creates an opening for Bayer to establish Nuviva as the primary challenger to Pfizer's Viagra in the oral erectile dysfunction class
Lilly Cialis Delay Clears Space For Bayer Nuviva: Extra FDA Caution Cited
The delay in the FDA review of Lilly/Icos' Cialis creates an opening for Bayer to establish Nuviva as the primary challenger to Pfizer's Viagra in the oral erectile dysfunction class
TAP Uprima 3 Mg Dose Studies To Be Completed This Summer; NDA Withdrawn
TAP expects to complete additional Uprima efficacy and safety studies using a 3 mg dose this summer.